The latest clinical advances of Ascenctage-B (06855), Nilotinib, Decitabine, and APG-5918 will be presented at the American Society of Hematology (ASH) Annual Meeting in 2025, including one oral presentation.

ASCENTAGE-B (06855) announced that three products (Nilevad, Lixetuximab, APG-5918) of the company have been selected to be presented and reported at the 67th American Society of Hematology (ASH) Annual Meeting, showcasing multiple clinical and preclinical advances, including one oral presentation. Specifically, the company's original first-line drug, Olevatinib (trade name: Nilevad), has been selected for the 67th ASH Annual Meeting with multiple clinical advances, marking the product's 8th consecutive year of being selected for the ASH Annual Meeting. Additionally, the company's original first-line drug, Lishatoclax (trade name: Lixetuximab; research code: APG-2575), has two clinical advancements selected for the 67th ASH Annual Meeting, with one oral presentation. This marks the product's 4th consecutive year of being selected for the ASH Annual Meeting. Nilevad is the first third-generation BCR-ABL inhibitor to be approved for marketing in China, and its commercial promotion in China is jointly managed by Ascend Pharmaceuticals and INNOVENT BIO. At this ASH Annual Meeting, Ascend Pharmaceuticals will be releasing the latest data from the Phase III global study (POLARIS-1) of Nilevad combined with low-intensity chemotherapy for newly diagnosed (ND) Ph+ acute lymphoblastic leukemia (ALL) patients. In addition, the 4-year follow-up data from the randomized controlled Phase II study of Nilevad in treating TKI-resistant CML-CP patients, as well as data from its second-line treatment in non-T315I mutated CML-CP patients, will also be updated at this meeting. Lishatoclax is a novel oral Bcl-2 selective inhibitor independently developed by Ascend Pharmaceuticals, with broad therapeutic potential in various hematological and solid tumor treatment areas. The product has been approved for marketing in China for use in adult patients with CLL/SLL who have undergone at least one systemic treatment, including a BTK inhibitor. Ascend Pharmaceuticals will present the latest developments from the Phase II clinical study of single-agent treatment of relapsed/refractory (R/R) CLL/SLL patients at this ASH Annual Meeting. Additionally, the latest data from the clinical study of Lishatoclax in combination with azacitidine (AZA) for previously untreated or relapsed/refractory myeloid neoplasm patients will also be presented in a poster format. The annual ASH Annual Meeting is one of the largest international academic conferences in the field of hematology, covering research on the causes and treatment of blood diseases comprehensively. The 67th ASH Annual Meeting will be held in a combined online and offline format in Orlando, Florida, USA, from December 6 to December 9, 2025.